Docetaxel plus oxaliplatin for advanced gastric cancer
Author Information
Author(s): Kim J G, Sohn S K, Chae Y S, Song H S, Kwon K-Y, Do Y R, Kim M K, Lee K H, Hyun M S, Ryoo H M, Bae S H, Park K U, Lee W S, Baek J H, Chung H Y, Yu W
Primary Institution: Kyungpook National University Hospital
Hypothesis
The study aims to evaluate the efficacy and safety of a combination regimen of docetaxel plus oxaliplatin in patients with advanced gastric cancer.
Conclusion
The combination of docetaxel and oxaliplatin was found to be well tolerated and effective in patients with advanced gastric cancer.
Supporting Evidence
- One complete response and 18 partial responses were confirmed, giving an overall response rate of 45.2%.
- The median time to progression was 5.7 months and median overall survival was 9.9 months.
- Grade 3/4 neutropenia occurred in 26.1% of patients.
Takeaway
Doctors tested a new medicine combination to help people with stomach cancer, and it worked pretty well without causing too many problems.
Methodology
Patients with untreated metastatic or recurrent gastric cancer received intravenous docetaxel and oxaliplatin on a 3-week cycle.
Potential Biases
Potential bias due to the single-arm design and lack of a control group.
Limitations
The study was limited to a small sample size and a short follow-up period.
Participant Demographics
Median age was 58 years, with 33 males and 9 females; 71.4% had metastatic disease.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI; 31.7–59.7%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website